In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SkyePharma PLC

http://www.skyepharma.com

Latest From SkyePharma PLC

Merck KGaA Finds The Right Home For Disease-Modifying OA Agent In Novartis

Novartis has added an anti-osteoarthritic Nanobody, M6495, to its growing pipeline of candidates for the condition, in a €450m agreement with Merck KGaA that sees the latter deliver on its plans to find new homes for its osteoarthritis pipeline.

Deals Orthopedics

Finance Watch: Big VC Money Backs Tech-Enabled Drug Discovery

Private Company Edition: XtalPi raised $318.8m for its AI-based drug discovery platform and machine learning-enabled Flagship start-up Valo Health has brought in nearly $100m. XtalPi had one of three recent venture capital mega-rounds for China-based companies.

Financing Artificial Intelligence

Phase II Win For Merck KGaA/Avillion Psoriasis Drug May Be Too Late

The German major is looking for a partner to advance its IL-17A/IL-17F nanobody sonelokinab for psoriasis but the search could be tricky given the strength of Novartis's Cosentyx and Eli Lilly's Taltz, while UCB's IL-17A and IL-17F inhibitor bimekizumab is likely to be approved soon.

Immune Disorders Clinical Trials

Coronavirus Update: Sanofi and GSK ‘Happy To Lose’ COVID-19 Vaccine Race

Heads of vaccines development at partners GSK and Sanofi:“This is not a sprint, it’s a marathon.”

Coronavirus COVID-19 Companies
See All

Company Information

UsernamePublicRestriction

Register